Relmada Therapeutics, Inc. (RLMD)
| Market Cap | 630.87M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.46M |
| Shares Out | 15.59M |
| EPS (ttm) | -3.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $37.13 |
| Previous Close | $37.67 |
| Change ($) | -0.54 |
| Change (%) | -1.43% |
| Day's Open | 37.53 |
| Day's Range | 36.74 - 37.82 |
| Day's Volume | 50,825 |
| 52-Week Range | 28.40 - 54.00 |
NEW YORK, May 6, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will ...
NEW YORK, May 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical...
NEW YORK, April 29, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data ...
NEW YORK, April 28, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergi...
NEW YORK, April 27, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data ...
NEW YORK, April 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the initiat...
NEW YORK, March 23, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate...
NEW YORK, March 18, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it wi...
NEW YORK, March 11, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergi...
Investors need to pay close attention to Relmada (RLMD) stock based on the movements in the options market lately.
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that the fir...
NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cl...
Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.
NEW YORK, May 29, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today an...
NEW YORK, May 26, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today an...
Should investors be excited or concerned about Relmada Therapeutics' attempt to treat severe depression with a variant of methadone?
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q2.
Relmada Therapeutics: A Promising Depression Focused Player For 2020
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1.
Relmada Therapeutics Inc. shares RLMD, +141.79% soared 137% Tuesday, after the clinical-stage biotech reported positive results from a midstage trial of a treatment for depression.
About RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid an... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 2004 |
| CEO Sergio Traversa | Employees 14 |
| Stock Exchange NASDAQ | Ticker Symbol RLMD |
Analyst Forecasts
According to 6 analysts, the average rating for RLMD stock is "Strong Buy." The 12-month stock price forecast is 63.67, which is an increase of 71.48% from the latest price.